Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.04 · Revenue $55.44M · 3 analysts
Est. EPS $-0.05 · Revenue $51.05M · 3 analysts
Est. EPS $-0.03 · Revenue $247.73M · 4 analysts
Est. EPS $0.01 · Revenue $50.69M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $311.1M | +1.5% | -0.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-178.0M | -156.1% | +63.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +33.5% | -27.1% | +47.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -11.6% | +49.0% | -442.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -57.2% | -152.3% | +63.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-237000 | +87.1% | -135.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -0.1% | +87.3% | -136.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 69.7% | -36.7% | +36.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.89x | +32.3% | +59.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $502.6M | -41.5% | -13.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.55 vs 0.20 | -1378.1% | -0.55 vs -0.04 | -1140.5% |
| Revenue Surprise | $311.1M vs $310.4M | +0.2% | $70.5M vs $55.4M | +27.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Larson-Green Julie | director | Common Stock | A | 9,766 | — |
| Sep 1, 2026 | Alger Jason | officer: Chief Financial Officer | Common Stock | D | 17,973 | $1.70 |
| Sep 1, 2026 | Albert Benjamin | director, officer: CEO | Common Stock | D | 321 | $1.70 |
| Sep 1, 2026 | Landry Benjamin | officer: General Counsel | Common Stock | D | 13,167 | $1.70 |
| Jul 16, 2026 | Hoggard Green Jill | director | Common Stock | A | 80,691 | — |
Operator : Welcome to the Health Catalyst Second Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Stephanie St. Clair, Senior Vice President of Finance and Investor Relations. Please go ahead, ma'am. Stephanie St. Clair : Good afternoon, and welcome to Health Catalyst's earnings conference call for the second quarter of 2026, which ended June 30, 2026. My name is Stephanie St. Clair, Finance and Investor Relations, Senior Vice President. With me on the call today are Ben Albert, our Chief Executive Officer; and Jason Alger, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today, as well as in our latest Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. As a reminder, today's call is being recorded, and a replay will be available following the conclusion of the call. During today's call, we will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including regarding our future growth and priorities, financial outlook and expectations for the third quarter and full year 2026, market conditions, AI initiatives, bookings, retention, operational priorities, strategic and restructuring initiatives, cost savings, debt elimination, client migrations, the impact of the Vitalware divestiture and the general anticipated performance of our business. These forward-looking statements are based on management's current views and expectations as of today and should not be relied on as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statements or outlook. Actual results may materially differ. Please refer to the risk factors in our most recent Form 10-K for the full year 2025 filed with the SEC on March 12, 2026, and our Form 10-Q for the second quarter of 2026 filed today. We will also refer to certain non-GAAP financial measures to provide additional information to investors. Non-GAAP financial information is presented for supplemental purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation of non-GAAP financial measures to the most comparable GAAP measures is provided in our press release. We will provide forward-looking guidance for certain non-GAAP financial measures in this earnings call and are not providing forward-looking guidance for the most directly comparable GAAP measures and therefore, have not provided reconciliations because there are items that may impact the comparable GAAP measures that are not within our control or cannot be reasonably forecasted. With that, I'll turn the call over to Ben. Benjamin Albert : Thank you, Stephanie, and thank you to everyone for joining us today. We …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Benjamin Albert | Chief Executive Officer & Director | USD 937,887 | Male | 1973 | Active |
Linda Llewelyn | Senior Advisor | USD 485,113 | Female | 1967 | Active |
Benjamin Landry | General Counsel & Secretary of the Board | USD 419,036 | Male | 1982 | Active |
Jason Alger | Chief Financial Officer | USD 365,366 | Male | 1984 | Active |
Kyle J. Salyers | Chief Strategy Officer & Senior Vice President of Corporate Development | — | Male | — | Active |
Jeffrey Selander | Senior Vice President of International | — | Male | — | Active |
Holly Rimmasch | Senior Vice President & Chief Clinical Officer | — | Female | — | Active |
Sadiqa Mahmood | GM & Senior VP of Life Sciences Business | — | Female | — | Active |
Kristen Berry | Senior Vice President of Public Relations | — | — | — | Active |
Carrie Kozlowski | Chief Marketing Officer | — | Female | — | Active |
Hsbc Holdings PLC bought a new stake in Health Catalyst, Inc. (NASDAQ: HCAT) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 408,634 shares of the company's stock, valued at approximately $809,000. Hsbc Holdings PLC owned approximately 0.54% of Health Catalyst
SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Aclarion (NASDAQ: ACONW - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations. Insider and Institutional Ownership 85.0% of Health Catalyst shares
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average rating of "Hold" from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Lynx Global Digital Finance (OTCMKTS:CNONF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership. Earnings and Valuation This table compares
